Clinical Trials on Plasma Cell Disorder in United States

Total 71661 results

University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Unusual Cancers of Childhood

United States
Cancer Treatment Centers of America

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Childhood Langerhans Cell Histiocytosis

United States
University of Kansas Medical Center
Eisai Inc.

Completed

Multi-day Doses in Prevention of Nausea and Emesis

Lymphoma, Malignant | Myeloma, Plasma-Cell

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (Bu Flu TBI)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Myelodysplastic/Myeloproliferative Neoplasms

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
St. Bartholomew's Hospital

Unknown

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
National Cancer Institute (NCI)

Completed

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Leukemia | Plasma Cell Myeloma | Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
Fred Hutchinson Cancer Center

Completed

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

No longer available

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Secondary Myelofibrosis

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Sanofi

Active, not recruiting

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA)

Plasma Cell Myeloma Recurrent

Taiwan, Brazil, Greece, Japan, Turkey, Czechia, France, Norway, Chile, Spain, United Kingdom, Argentina, United States, Australia, Canada, China, Germany, Hungary, Italy, Poland, Sweden
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Plasma Cell Myeloma | Chemotherapy-induced Peripheral Neuropathy

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Secondary Amyloidosis

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Sanofi

Completed

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)

Plasma Cell Myeloma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | EBV Positive Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Smoldering Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Pain | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Psychosocial Effects of Cancer and Its Treatment | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Terminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Fanconi Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Diamond-blackfan Anemia

United States
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Completed

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Sanofi

Terminated

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Plasma Cell Myeloma

Taiwan, United States, Czechia, France, Greece, Spain
Case Comprehensive Cancer Center

Completed

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Psychosocial Effects of Cancer and Its Treatment

United States
Roswell Park Cancer Institute

Completed

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Barbara Ann Karmanos Cancer Institute

Completed

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Standardized Nursing Intervention Protocol for HCT Patients

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Psychosocial Effects of Cancer and Its Treatment | Myelodysplastic/Myeloproliferative Neoplasms | Therapy-related Toxicity

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States

Clinical Trials on Plasma Cell Disorder in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations